Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

London, United Kingdom (PressExposure) March 15, 2011 -- GlobalData estimated the global diabetic foot ulcer (DFU) market to be worth $1028m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 15.4% to reach $2,799m by 2017. This high growth forecast is primarily attributed to an increase in the diabetic patient population which will lead to increases in DFU incidence and prevalence, along with non-compliance to insulin therapy and emergence of more therapeutic options. The strong product pipeline will complement the existing products by providing effective treatment options.

GlobalData found that the products currently in the market are highly efficacious in providing protection against the disease with minimum side-effects. All the market products are having high safety and efficacy profiles. The key products such as Invanz (ertapenam), Zyvox(linezolid), Zosyn(piperacillin/tazobactam), and Regranex(becaplermin) are able to satisfy the demand in the DFU market. The unmet need arises from the fact that most of the marketed products are intended to prevent the infection of DFU. So the market is expecting drugs with novel mechanisms of action to accelerate ulcer healing and tissue regeneration Unmet Need in the DFU Market is Low, Mostly Associated with Available Antibiotic Segments

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx?ID=Diabetic-Foot-Ulcer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

GlobalData, the industry analysis specialist, has released its new report, "Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global diabetic foot ulcer market. The report identifies the key trends shaping and driving the global diabetic foot ulcer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global diabetic foot ulcer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Diabetic-Foot-Ulcer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

About Globaldata

GlobalData is an industry analysis specialist, providing business information products and services. GlobalData's highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge.

Press Release Source: http://PressExposure.com/PR/Globaldata.html

Press Release Submitted On: March 15, 2011 at 1:23 am
This article has been viewed 56765 time(s).